Calcimedica, INC

CalciMedica, Inc. announced an expansion of its Board of Directors with the appointment of Dr. Evgeny Zaytsev and the upcoming retirement of director Fred Middleton.

CalciMedica has entered into a definitive securities purchase agreement for a private placement of up to approximately $49 million to advance its pulmonary hypertension program.

CalciMedica has amended its loan agreement with Avenue Capital, extending the maturity date to 2029 and lowering warrant exercise prices to $1.00.

CalciMedica announced its first quarter 2026 financial results, highlighting progress in its Auxora program for acute pancreatitis and advancement of its CM5480 candidate for pulmonary hypertension, alongside a net income of $5.0 million.

CalciMedica, Inc. received notices from Nasdaq regarding non-compliance with minimum market value and bid price requirements, risking delisting.

CalciMedica announced its 2025 financial results, discontinued the AKI KOURAGE trial due to a mortality imbalance but no drug toxicity, and advanced Auxora for acute pancreatitis while progressing CM5480 for PAH.

CalciMedica, Inc. announced its first quarter 2026 financial results, reporting a net income of $5.0 million, a significant turnaround from the prior year's net loss.

CalciMedica, a clinical-stage biopharmaceutical company, reported increased net losses and expressed substantial doubt about its ability to continue as a going concern, despite securing new debt financing and expanding its ATM facility.

CalciMedica, a clinical-stage biopharmaceutical company, reported increased net losses and a 'substantial doubt' about its ability to continue as a going concern, despite ongoing clinical trial progress for its lead candidate, Auxora.

CalciMedica, a clinical-stage biopharmaceutical company, announces its financial results for the first quarter of 2025, highlighting ongoing clinical trials and financial activities.

CalciMedica's Q3 2024 report details financial results and provides updates on clinical trials, including the ongoing Phase 2 trial for Auxora in acute kidney injury.

CalciMedica's Q2 2024 report shows a net loss of $3.8 million, offset by gains in fair value of financial instruments and a private placement, as the company advances its clinical programs.

CalciMedica, Inc. filed an amendment to its 2025 Annual Report to provide updated corporate governance and executive compensation disclosures.

CalciMedica's 10-K filing summarizes the company's financial status, clinical trial progress, and future plans, emphasizing its focus on CRAC channel inhibitors for inflammatory diseases.

CalciMedica has filed an amendment to its annual report on Form 10-K to include previously omitted information regarding directors, executive officers, and corporate governance.

CalciMedica's 10-K filing outlines the company's capital structure, anti-takeover provisions, and regulatory compliance, highlighting its focus on developing CRAC channel inhibitors.

CalciMedica, Inc. reports that Director Evgeny Zaytsev acquired stock options for 20,000 shares.

Fred A. Middleton, a Director and 10% Owner of CalciMedica, Inc., acquired 248,972 shares of common stock on June 25, 2026, through a Securities Purchase Agreement.

CalciMedica Chief Medical Officer Sudarshan Hebbar acquired 124,486 shares of common stock.

CalciMedica Director Robert N. Wilson acquired over 1.1 million shares of common stock in a private placement.

Eric W. Roberts, a Director and Chief Business Officer of CalciMedica, Inc., acquired 186,729 shares of common stock on June 25, 2026, through a Securities Purchase Agreement.

CalciMedica CEO Rachel Leheny acquired 186,729 shares of common stock in a private placement transaction on June 25, 2026.

CalciMedica, Inc. announced its 2026 Annual Meeting of Stockholders, scheduled for August 19, 2026, to vote on several critical proposals including a reverse stock split, equity plan amendments, and warrant issuances.

CalciMedica, Inc. has informed stockholders of a change in its independent registered public accounting firm from Moss Adams LLP to Baker Tilly US, LLP, effective June 3, 2025, due to a merger between the two accounting firms.

CalciMedica, Inc. will hold its annual stockholders meeting on June 24, 2025, to elect directors, ratify the appointment of its accounting firm, and approve an amendment to its equity incentive plan.

CalciMedica is asking stockholders to approve an amendment to its 2023 Equity Incentive Plan to increase the number of shares available for issuance by 600,000.

CalciMedica, Inc. will hold its annual meeting on August 27, 2024, to vote on the election of directors, ratification of auditors, and an amendment to the equity incentive plan.

CalciMedica is holding its annual stockholder meeting on August 27, 2024, to vote on the election of directors, ratification of the accounting firm, and an amendment to the equity incentive plan.

Alafi Capital Company LLC and Christopher D. Alafi have reported beneficial ownership of 17.1% of CalciMedica, Inc. common stock following a recent private placement.

Bering Partners II, L.P. and related entities have disclosed their beneficial ownership of CalciMedica, Inc. common stock, representing a 6.9% stake following a recent private placement.

Valence Investments and key individuals report changes in beneficial ownership of CalciMedica, Inc. common stock, including participation in a recent public offering.

CVI Investments, Inc. and Heights Capital Management, Inc. jointly file Schedule 13G, reporting beneficial ownership of 5.1% of CalciMedica, Inc. common stock.

Avenue Venture Opportunities Fund II has amended its loan agreement with CalciMedica, maintaining a 4.99% ownership blocker.

Jorey Chernett has filed an amendment to Schedule 13G confirming the complete divestment of all shares in CalciMedica, Inc.

Soleus Capital and affiliated entities report a 2.4% beneficial ownership stake in CalciMedica, Inc. through warrant holdings.

Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P., and James E. Flynn jointly reported beneficial ownership of 4.34% of CalciMedica Inc.'s common stock, primarily through warrants.

Jorey Chernett has reported beneficial ownership of 7.88% of CalciMedica, Inc.'s common stock as of November 24, 2025.